IHC - High Molecular Weight-Kininogen (HMW-K) Test Cost & Procedure

HMWK or HK  is a circulating plasma polypeptide that takes part at the beginning of blood coagulation, and the era of the vasodilation of bradykinin via the kallikrein-kinin strategy. HMWK is passive until it either cling to a binding polypeptide beneath an endothelium disrupted by a wound, thereby commencing clotting; or it attaches to intact endothelial compartments or platelets for procedures different than clotting

Arrangement and Procedure

HMWK is an alpha-globulin with six functional domains. It disseminates as a single-chain six hundred twenty-six amino acid polypeptides. The heavy chain contains the realm one, two, and three; the tiny chain, realms five and six. Realm four connects the weighty and tiny chains.

The professions contain the cult functional locations:

• Realm one - calcium binding
• Realm two - cysteine protease inhibition
• Realm three - cysteine protease inhibition; platelet and endothelial compartment binding
• Realm four - bradykinin era
• Realm five - heparin and compartment binding; antiangiogenic properties; binding to negatively accused textures
• Realm six - prekallikrein

HMWK is one of four polypeptides affixed to stimulate the affinity-triggering path of clotting: the other three are Factor 12, Factor 11, and prekallikrein. HMWK is not enzymatically enthusiastic and schemes only as a cofact r the triggering  of kallikrein. It is also crucial for the activation of factor 11by factor 12a.

HMWK is also a harbinger of bradykinin. This vasodilation is dismissed through favorable feedback by kallikrein.

Congenital

The gene for both LMWK and HMWK is found on the 3rd chromosome

Stature

Estimation of HMWK is usually accomplished with mixing analyses, in which plasma deficiency in HMWK is diverse with the patient's specimen, and a PTT is committed. Outcomes are conveyed in percent of normal - a significance under sixty percent demonstrates a shortcoming.

Clinical characteristics

The presence of HMWK was hypothesized in 1975 when several patients were characterized by weakness of a lesson of plasma polypeptide and a prolonged bleeding period and PTT. There is no raised hazard of bleeding or any different manifestation, so the shortcoming is a characteristic, not an illness.